Ebang International Holdings is a technology company primarily engaged in the design and manufacture of high-performance Bitcoin mining machines and related hardware
The company focuses on developing innovative solutions for cryptocurrency mining, catering to the growing demand in the digital asset industry. Additionally, Ebang is involved in blockchain technology research and development, aiming to enhance the efficiency and security of cryptocurrency transactions. Through its commitment to advancing mining technologies, Ebang seeks to position itself as a key player in the rapidly evolving landscape of digital currencies.
Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention.
U.S. stocks closed higher on Wednesday, with the Nasdaq Composite gaining more than 100 points. Here is the list of some big stocks recording losses in the previous session.
Gainers Dave Inc. (NASDAQ: DAVE) rose 56.9% to $0.9826 in pre-market trading. Dave is expected to release its second quarter 2022 financial results on Thursday, August 11, 2022.
Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares climbed 53.2% to close at $3.14 on Wednesday. Blue Water Vaccines recently announced signing of sponsored research agreement with Cincinnati Children's Hospital Medical Center for S&P vaccine platform development.
Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 67.8% to $3.4390. Blue Water Vaccines recently announced signing of sponsored research agreement with Cincinnati Children's Hospital Medical Center for S&P vaccine platform development.
Key Takeaways: Ebang, a maker of cryptocurrency mining machines, has been warned about potential delisting from the Nasdaq after its stock remained below $1 for a prolonged period Rival crypto mining equipment maker Canaan repurchased warrants it issued last year after its stock plunged to levels well below the exercise price
Gainers United Maritime Corporation (NASDAQ: USEA) climbed 147.6% to close at $7.08 on Thursday on heavy momentum following the company's recent listing on the Nasdaq Capital Market.
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric low-grade glioma showed an overall response rate of 64%.
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric low-grade glioma showed an overall response rate of 64%.
US equity futures reversed earlier losses and European stock markets rose as a sharp rally in crude oil stalled, even as a selloff in bonds deepened Tuesday after Fed Chair Powell signaled a stronger commitment to clamp down on inflation.
